Literature DB >> 1400509

Phosphorylation of the Rex protein of human T-cell leukemia virus type I.

Y Adachi1, T D Copeland, C Takahashi, T Nosaka, A Ahmed, S Oroszlan, M Hatanaka.   

Abstract

Rex protein, the posttranscriptional regulator of human T-cell leukemia virus type I (HTLV-I), is required for the control of viral structural protein expression and virus replication. Rex is a phosphoprotein found predominantly in the cell nucleolus, whose function is thought to be regulated by its nucleolar localization and phosphorylation. Therefore, we investigated the in vivo phosphorylation of Rex protein in more detail. Phosphorylation of Rex occurred in all HTLV-I-infected cell lines examined in vivo, primarily at serine residues and to a very small extent at threonine residues. Treatment of cells with 12-O-tetradecanoylphorbol-13-acetate (TPA) led to significant but transient enhancement of the incorporation of [32P]orthophosphate into Rex protein. N-terminal truncation of Rex protein abolished TPA-dependent phosphorylation. Chymotryptic digestion of phosphorylated Rex yielded two phosphopeptides. In vivo phosphorylation sites were identified as serine residues 70 and 177 and threonine residue 174. Serine 70 was a TPA-dependent phosphorylation site within a regulatory domain. We have already shown that the protein kinase C inhibitor H-7 (1-(5-isoquinolinylsulfonyl)-2-methylpiperazine) specifically blocked accumulation of viral unspliced gag-pol mRNA. Therefore, the phosphorylation at serine 70 may be involved in the regulation of Rex function in response to extracellular stimuli.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400509

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  The human T-cell leukemia virus Rex protein.

Authors:  Ihab Younis; Patrick L Green
Journal:  Front Biosci       Date:  2005-01-01

2.  Nuclear export and expression of human T-cell leukemia virus type 1 tax/rex mRNA are RxRE/Rex dependent.

Authors:  X T Bai; U Sinha-Datta; N L Ko; M Bellon; C Nicot
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 3.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

4.  Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein.

Authors:  S Kubota; L Duan; R A Furuta; M Hatanaka; R J Pomerantz
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

5.  Human T-cell leukemia virus type 1 expressing nonoverlapping tax and rex genes replicates and immortalizes primary human T lymphocytes but fails to replicate and persist in vivo.

Authors:  Ihab Younis; Brenda Yamamoto; Andrew Phipps; Patrick L Green
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 6.  Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1).

Authors:  J M Johnson; R Harrod; G Franchini
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

Review 7.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

8.  Human T-cell leukemia virus type 2 Rex carboxy terminus is an inhibitory/stability domain that regulates Rex functional activity and viral replication.

Authors:  Li Xie; Matthew Kesic; Brenda Yamamoto; Min Li; Ihab Younis; Michael D Lairmore; Patrick L Green
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

Review 9.  HTLV-1 Yin and Yang: Rex and p30 master regulators of viral mRNA trafficking.

Authors:  Hicham H Baydoun; Marcia Bellon; Christophe Nicot
Journal:  AIDS Rev       Date:  2008 Oct-Dec       Impact factor: 2.500

10.  Phosphorylation regulates human T-cell leukemia virus type 1 Rex function.

Authors:  Matthew Kesic; Rami Doueiri; Michael Ward; O John Semmes; Patrick L Green
Journal:  Retrovirology       Date:  2009-11-17       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.